Trials / Completed
CompletedNCT03003494
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 306 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
Detailed description
Purpose:
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spiolto® Respimat® | observations taken in a period of approximately 6 weeks |
Timeline
- Start date
- 2017-06-06
- Primary completion
- 2018-07-30
- Completion
- 2018-07-30
- First posted
- 2016-12-28
- Last updated
- 2019-09-30
- Results posted
- 2019-09-30
Locations
28 sites across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03003494. Inclusion in this directory is not an endorsement.